# REC-7735 in Participants With Solid Tumors

Source: https://onco.cc/trials/nct07819136/  
OnCo record `nct07819136` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of REC-7735 run by Recursion Pharmaceuticals Inc., now recruiting.

## Summary

REC-7735 in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT07819136 by Recursion Pharmaceuticals Inc., with 90 participants planned, started 2026-09. Conditions recorded: Solid Tumors. Interventions recorded: REC-7735.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07819136
- Phase: 1/2
- Setting: A Phase 1 / 2, Open-Label Study of REC-7735 in Participants With Unresectable, Locally Advanced, or Metastatic PIK3CA-H1047R Mutated Solid Tumors
- Sponsor: Recursion Pharmaceuticals Inc.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT07819136: https://clinicaltrials.gov/study/NCT07819136

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [REC-7735](https://onco.cc/drugs/rec-7735/)
- companies: [Recursion Pharmaceuticals](https://onco.cc/companies/recursion/)

---
JSON: https://onco.cc/api/v1/entities/nct07819136.json